Clinically, Jagged1 overexpression is strongly associated with poor prognosis, high tumor grade, and increased metastatic potential in a variety of human cancers, including prostate cancer [153], tongue squamous cell carcinoma [154], renal cell carcinoma [155], breast cancer [156], pancreatic cancer [157], multiple myeloma [158,159] and ovarian cancer [160]. This evidence concerns the gene JAG1 and ovarian cancer.